Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Ikena Oncology stock | $11.16

Learn how to easily invest in Ikena Oncology stock.

Ikena Oncology Inc is a biotechnology business based in the US. Ikena Oncology shares (IKNA) are listed on the NASDAQ and all prices are listed in US Dollars. Ikena Oncology employs 50 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Ikena Oncology

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IKNA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Ikena Oncology stock price (NASDAQ: IKNA)

Use our graph to track the performance of IKNA stocks over time.

Ikena Oncology shares at a glance

Information last updated 2021-10-17.
Latest market close$11.16
52-week range$9.63 - $37.61
50-day moving average $12.81
200-day moving average $15.01
Wall St. target price$27.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.79

Buy Ikena Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ikena Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ikena Oncology price performance over time

Historical closes compared with the close of $11.16 from 2021-10-21

1 week (2021-10-15) -7.84%
1 month (2021-09-22) -14.09%
3 months (2021-07-22) -3.96%
6 months (2021-04-22) -44.28%
1 year (2020-10-18) N/A
2 years (2019-10-18) N/A
3 years (2018-10-18) N/A
5 years (2016-10-18) N/A

Ikena Oncology financials

Revenue TTM $9.9 million
Gross profit TTM $-24,513,000
Return on assets TTM -16.4%
Return on equity TTM -72.35%
Profit margin 0%
Book value $6.03
Market capitalisation $509.5 million

TTM: trailing 12 months

Shorting Ikena Oncology shares

There are currently 1.3 million Ikena Oncology shares held short by investors – that's known as Ikena Oncology's "short interest". This figure is 14.4% down from 1.5 million last month.

There are a few different ways that this level of interest in shorting Ikena Oncology shares can be evaluated.

Ikena Oncology's "short interest ratio" (SIR)

Ikena Oncology's "short interest ratio" (SIR) is the quantity of Ikena Oncology shares currently shorted divided by the average quantity of Ikena Oncology shares traded daily (recently around 97940.314136126). Ikena Oncology's SIR currently stands at 13.37. In other words for every 100,000 Ikena Oncology shares traded daily on the market, roughly 13370 shares are currently held short.

To gain some more context, you can compare Ikena Oncology's short interest ratio against those of similar companies.

However Ikena Oncology's short interest can also be evaluated against the total number of Ikena Oncology shares, or, against the total number of tradable Ikena Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ikena Oncology's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Ikena Oncology shares in existence, roughly 30 shares are currently held short) or 0.086% of the tradable shares (for every 100,000 tradable Ikena Oncology shares, roughly 86 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Ikena Oncology.

Find out more about how you can short Ikena Oncology stock.

Ikena Oncology share dividends

We're not expecting Ikena Oncology to pay a dividend over the next 12 months.

Ikena Oncology overview

Ikena Oncology, Inc. , a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. .

Frequently asked questions

What percentage of Ikena Oncology is owned by insiders or institutions?
Currently 0.08% of Ikena Oncology shares are held by insiders and 57.122% by institutions.
How many people work for Ikena Oncology?
Latest data suggests 50 work at Ikena Oncology.
When does the fiscal year end for Ikena Oncology?
Ikena Oncology's fiscal year ends in December.
Where is Ikena Oncology based?
Ikena Oncology's address is: 645 Summer Street, Boston, MA, United States, 02210
What is Ikena Oncology's ISIN number?
Ikena Oncology's international securities identification number is: US45175G1085

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site